| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥13.1B | ¥24.5B | -46.7% |
| Operating Income | ¥-44.4B | ¥-38.8B | - |
| Ordinary Income | ¥-46.5B | ¥-36.9B | - |
| Net Income | ¥-49.0B | ¥-39.2B | - |
| ROE | -385.3% | -93.5% | - |
FY2025 quarterly results show severe deterioration with Revenue of 1.3B yen (YoY -46.7%), Operating Loss of -4.4B yen (expanded from -3.9B yen prior year), Ordinary Loss of -4.6B yen (worsened from -3.7B yen), and Net Loss of -4.9B yen (deteriorated from -3.9B yen). The company faces substantial cash consumption with operating cash flow of -4.6B yen and cash reserves declining 27.3% YoY to 2.9B yen. Full-year guidance projects Revenue of 3.9B yen (implying 97.5% increase from quarterly run rate) with Operating Loss of -4.2B yen, requiring significant revenue recovery and cost restructuring to achieve.
[Profitability] Operating margin of -339.7% reflects fundamental mismatch between revenue generation and cost structure, with selling, general and administrative expenses of 5.4B yen exceeding revenue by 4.1x. Gross profit margin remains favorable at 72.5%, indicating product-level profitability is preserved, but massive fixed cost burden eliminates all profitability. ROE of -375.5% demonstrates severe earnings deterioration, driven by net profit margin of -365.4%, asset turnover of 0.34x, and financial leverage of 3.04x. [Cash Quality] Cash and deposits of 2.9B yen decreased 1.1B yen from prior year, with short-term debt coverage ratio of 3.31x based on current cash position. Operating cash flow to net income ratio of 0.96x indicates cash outflow closely tracks accounting losses. [Investment Efficiency] Asset turnover of 0.34x reflects low revenue generation relative to asset base. Days inventory outstanding extended to 155 days (up from shorter periods), while days sales outstanding stands at 73 days, indicating working capital inefficiency. [Financial Health] Equity ratio of 32.9% (down from 84.5% prior year) shows rapid balance sheet deterioration. Current ratio of 296.4% and quick ratio of 284.5% appear adequate for near-term liquidity, but debt-to-equity ratio of 2.04x exceeds typical leverage thresholds. Net debt position and leverage metrics indicate elevated financial risk given ongoing cash consumption.
Operating cash flow of -4.6B yen directly reflects operating loss of -4.4B yen, with minimal divergence between accrual earnings and cash generation indicating losses are cash-backed. Cash consumption rate of approximately 1.5B yen per quarter based on current trajectory places significant pressure on remaining cash reserves of 2.9B yen. Investing cash flow of -0.1B yen included minimal capital expenditures of 0.02B yen, demonstrating restrained investment activity during loss period. Financing cash flow of positive 3.6B yen provided temporary relief through external capital raising, partially offsetting operating cash consumption. Free cash flow of -4.7B yen confirms the company is burning through cash at substantial rate. Working capital movements show accounts receivable decreased 0.2B yen as collections proceeded, while inventory increased 0.04B yen despite revenue decline, suggesting demand weakness or sales timing issues. The combination of persistent operating cash outflow and declining cash reserves creates urgency for either revenue recovery or additional financing within next 6-9 months based on current burn rate.
Ordinary loss of -4.6B yen compared to operating loss of -4.4B yen indicates non-operating net expense of approximately 0.2B yen, representing 1.5% of revenue. Non-operating expenses consist primarily of financial costs and other recurring items without material one-time gains masking operating performance. The alignment between operating losses and ordinary losses confirms earnings quality concerns stem from core business operations rather than non-operating volatility. Operating cash flow closely tracks net income at 96% ratio, suggesting limited accrual manipulation, though both metrics are deeply negative. The negative 4.6B yen operating cash flow matching 4.8B yen net loss demonstrates that accounting losses translate to actual cash consumption. Gross profit margin preservation at 72.5% indicates revenue quality remains intact at product level, with profitability issues concentrated in cost structure. No significant non-recurring gains were identified that would artificially inflate reported earnings, and the persistent losses across both accrual and cash metrics confirm genuine operational challenges requiring fundamental business model adjustment.
Revenue concentration risk is evident from 46.7% year-over-year decline, suggesting dependence on limited number of products, licensing agreements, or customers whose contribution has materially contracted. Company's ability to achieve full-year revenue guidance of 3.9B yen (requiring nearly 3x increase from current quarterly run rate) faces high execution uncertainty. Cash runway risk emerges from 27.3% decline in cash reserves to 2.9B yen against quarterly cash consumption of approximately 1.5B yen, implying potential funding requirement within 6-9 months absent significant operational improvement. Leverage risk reflected in debt-to-equity ratio of 2.04x limits financing flexibility and increases cost of capital for any future fundraising. Cost structure rigidity poses critical risk as selling, general and administrative expenses of 5.4B yen remain fixed despite revenue collapse, with limited evidence of aggressive cost reduction efforts proportionate to revenue decline.
[Industry Position] (Reference - Proprietary Analysis) Historical performance shows Operating Margin deteriorating to -339.7% in 2025, representing substantial deviation from sustainable business operations. Net Profit Margin of -375.0% in 2025 reflects intensification of losses. Revenue Growth of -46.7% YoY in 2025 indicates severe contraction in commercial activities. Without comparable industry benchmark data for this specific biotechnology development stage, general observations indicate the company is operating in pre-commercial or early commercial phase typical of development-stage biopharmaceutical companies, where high R&D and administrative costs precede revenue generation. The magnitude of losses and cash consumption rate suggest the company is in critical phase requiring either significant pipeline advancement, partnership agreements, or additional capital to bridge to profitability. Industry characteristics typically include high cash burn during development phase, dependency on milestone payments and licensing revenue, and eventual transition to product revenue upon commercialization, though timing and success probability vary substantially across companies.
Fundamental business model misalignment is observed where operating expenses of 5.8B yen exceed quarterly revenue of 1.3B yen by 4.4x, requiring either revenue multiplication or cost restructuring of 70-80% to approach breakeven. Current trajectory projects cash depletion within 6-9 months based on 1.5B yen quarterly burn rate against 2.9B yen cash reserves, creating near-term financing imperative. The company's full-year guidance implies substantial second-half acceleration with revenue increasing approximately 3x from current run rate and narrowing of operating loss, representing high-conviction forecast requiring verification of underlying commercial or partnership catalysts. Capital structure has shifted materially with equity ratio declining from 84.5% to 32.9% and debt-to-equity ratio reaching 2.04x, indicating prior equity cushion has eroded and future financing likely faces higher cost or dilution given elevated risk profile.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.